ANCA Are Detectable in Nearly All Patients with Active Severe Wegener’s Granulomatosis

Hoffman, 1998, Anti-neutrophil cytoplasmic antibodies, Arthritis Rheum, 41, 1521, 10.1002/1529-0131(199809)41:9<1521::AID-ART2>3.0.CO;2-A Savige, 2000, Antineutrophil cytoplasmic antibodies and associated diseases: a review of the clinical and laboratory features, Kidney Int, 57, 846, 10.1046/j.1523-1755.2000.057003846.x Hoffman, 2005, Are there different forms of life in the antineutrophil cytoplasmic antibody universe?, Ann Intern Med, 143, 683, 10.7326/0003-4819-143-9-200511010-00012 Rao, 1995, The role of antineutrophil cytoplasmic antibody (c-ANCA) testing in the diagnosis of Wegener granulomatosis, Ann Intern Med, 123, 925, 10.7326/0003-4819-123-12-199512150-00005 Nölle, 1989, Anticytoplasmic autoantibodies: their immunodiagnostic value, Ann Intern Med, 111, 28, 10.7326/0003-4819-111-1-28 Lim, 1999, Diagnostic usefulness of antineutrophil cytoplasmic autoantibody serology, Am J Clin Pathol, 111, 363, 10.1093/ajcp/111.3.363 Csernok, 2002, A critical evaluation of commercial immunoassays for antineutrophil cytoplasmic antibodies directed against proteinase 3 and myeloperoxidase in Wegener’s granulomatosis and microscopic polyangiitis, Rheumatology (Oxford), 41, 1313, 10.1093/rheumatology/41.11.1313 Csernok, 2004, Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener’s granulomatosis: first results from a multicentre study, Rheumatology (Oxford), 43, 174, 10.1093/rheumatology/keh028 Sun, 1998, Capture-ELISA based on recombinant PR3 is sensitive for PR3-ANCA testing and allows detection of PR3 and PR3-ANCA/PR3 immune complexes, J Immunol Methods, 211, 111, 10.1016/S0022-1759(97)00203-2 Sun, 1998, A proportion of proteinase 3-specific anti-neutrophil cytoplasmic antibodies only react with proteinase 3 after cleavage of its N-terminal activation dipeptide, Clin Exp Immunol, 114, 320, 10.1046/j.1365-2249.1998.00730.x Russell, 2002, Detection of anti-neutrophil cytoplasmic antibodies under actual clinical testing conditions, Clin Immunol, 103, 196, 10.1006/clim.2001.5200 Lee, 2005, A novel capture-ELISA for detection of anti-neutrophil cytoplasmic antibodies (ANCA) based on c-myc peptide recognition in carboxy-terminally tagged recombinant neutrophil serine proteases, J Immunol Methods, 307, 62, 10.1016/j.jim.2005.09.004 2005, Etanercept plus standard therapy for Wegener’s granulomatosis, N Engl J Med, 352, 351, 10.1056/NEJMoa041884 2002, Design of the Wegener’s granulomatosis etanercept trial (WGET), Control Clin Trials, 23, 450, 10.1016/S0197-2456(02)00209-X 2003, Limited versus severe Wegener’s granulomatosis: baseline data on patients in the Wegener’s granulomatosis etanercept trial, Arthritis Rheum, 48, 2299, 10.1002/art.11075 Stone, 2001, A disease-specific activity index for Wegener’s granulomatosis: modification of the Birmingham Vasculitis Activity Score, Arthritis Rheum, 44, 912, 10.1002/1529-0131(200104)44:4<912::AID-ANR148>3.0.CO;2-5 Specks, 2004, Antineutrophil cytoplasmic antibodies: are they pathogenic?, Clin Exp Rheumatol, 22, S7 Xiao, 2002, Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice, J Clin Invest, 110, 955, 10.1172/JCI0215918 Little, 2005, Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo, Blood, 106, 2050, 10.1182/blood-2005-03-0921 Stone, 2004, A brief history of Wegener’s granulomatosis: on limited, localized, and generalized forms of the disease, Arthritis Rheum, 50, 335, 10.1002/art.11490